Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Molecular Cancer Therapeutics|March 17, 2018
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer TreatmentHetal Patel, Manikandan Periyasamy, Georgina P Sava, et al.
Nature Communications|November 28, 2015
Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasionVan T M Nguyen, Iros Barozzi, Monica Faronato, et al.
Breast Cancer Research and Treatment|July 8, 2010
The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cellsPaul T R Thiruchelvam, Chun-Fui Lai, Hui Hua, et al.
Nature Communications|August 8, 2019
Author Correction: Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasionVan T M Nguyen, Iros Barozzi, Monica Faronato, et al.
Breast Cancer Research and Treatment|August 24, 2010
Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growthRobert S Tolhurst, Ross S Thomas, Fiona J Kyle, et al.
Cancer Research|July 30, 2009
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activitySimak Ali, Dean A Heathcote, Sebastian H B Kroll, et al.
Cell Reports|September 29, 2015
APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast CancerManikandan Periyasamy, Hetal Patel, Chun-Fui Lai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2016
Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast CancerHetal Patel, Rezvan Abduljabbar, Chun-Fui Lai, et al.
Cancer Research|October 2, 2024
Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast CancerCarolina Gemma, Chun-Fui Lai, Anup K Singh, et al.
Journal of Medicinal Chemistry|November 18, 2010
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administrationDean A Heathcote, Hetal Patel, Sebastian H B Kroll, et al.
Pageof 3